RYSTIGGO^®

USA

In the U.S. RYSTIGGO® (rozanolixizumab-noli) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Prescribing information USA

RYSTIGGO^® prescribing information USA - June 2024

Europe

In Europe, RYSTIGGO^® (rozanolixizumab) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Prescribing information Europe

RYSTIGGO^® SmPC (Sourced from www.ema.europa.eu)